Related references
Note: Only part of the references are listed.DNA methylome alterations in chemical carcinogenesis
Igor P. Pogribny et al.
CANCER LETTERS (2013)
DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis
Wynand P. Roos et al.
CANCER LETTERS (2013)
Epigenetics and Colorectal Cancer Pathogenesis
Kankana Bardhan et al.
Cancers (2013)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs
Luis I. Toledo et al.
MOLECULAR ONCOLOGY (2011)
Demethylation by 5-aza-2′-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists
David Mossman et al.
BMC CANCER (2010)
Adjuvant chemotherapy for early colon cancer: What survival benefits make it worthwhile?
Prunella Blinman et al.
EUROPEAN JOURNAL OF CANCER (2010)
Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors
Lisa A. Cowan et al.
EPIGENOMICS (2010)
Decytabine enhances cytotoxicity induced by oxaliplatin and 5-fluorouracil in the colorectal cancer cell line Colo-205
Sylwia Flis et al.
CANCER CELL INTERNATIONAL (2009)
DNA Structure and Integrity Checkpoints during the Cell Cycle and Their Role in Drug Targeting and Sensitivity of Tumor Cells to Anticancer Treatment
Andrzej Skladanowski et al.
CHEMICAL REVIEWS (2009)
Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines
Francesco Crea et al.
MOLECULAR CANCER THERAPEUTICS (2009)
The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells
C. Flotho et al.
LEUKEMIA (2009)
Long-term Epigenetic Therapy with Oral Zebularine Has Minimal Side Effects and Prevents Intestinal Tumors in Mice
Christine B. Yoo et al.
CANCER PREVENTION RESEARCH (2008)
Early events in the mammalian response to DNA double-strand breaks
Lucy C. Riches et al.
MUTAGENESIS (2008)
DNA methylation inhibitor 5-aza-2 '-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B
Stela S. Palii et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors
Kim Appleton et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Adjuvant therapy in colon cancer - what, when and how?
I. Chau et al.
ANNALS OF ONCOLOGY (2006)
Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells
T Ben-Kasus et al.
BIOCHEMICAL PHARMACOLOGY (2005)
Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine
JL Holleran et al.
CLINICAL CANCER RESEARCH (2005)
Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells
JC Cheng et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
DNA damage-induced activation of ATM and ATM-dependent signaling pathways
EU Kurz et al.
DNA REPAIR (2004)
Preferential response of cancer cells to zebularine
JC Cheng et al.
CANCER CELL (2004)
Zebularine: a new drug for epigenetic therapy
CB Yoo et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2004)
Methylation of hMLH1 promoter correlates with the gene silencing with a region-specific manner in colorectal cancer
G Deng et al.
BRITISH JOURNAL OF CANCER (2002)
DNA methyltransferase inhibitors - state of the art
J Goffin et al.
ANNALS OF ONCOLOGY (2002)
Resveratrol induces colon tumor cell apoptosis independently of p53 and preceded by epithelial differentiation, mitochondrial proliferation and membrane potential collapse
M Mahyar-Roemer et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Share Paper
